BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27259909)

  • 1. [LDV/SOF successful in general practice test].
    Bischoff M
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259909
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sofosbuvir/ledipasvir is also effective in routine general practice].
    Warpakowski A
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interferon free recovery for almost all patients].
    Einecke D
    MMW Fortschr Med; 2015 Mar; 157(4):71. PubMed ID: 25743991
    [No Abstract]   [Full Text] [Related]  

  • 4. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
    Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
    J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
    Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing a broader user base for new HCV drug.
    Sekkides O
    Lancet Infect Dis; 2015 Apr; 15(4):383. PubMed ID: 25809898
    [No Abstract]   [Full Text] [Related]  

  • 7. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 8. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for hepatitis C--the costs of success.
    Hoofnagle JH; Sherker AH
    N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
    [No Abstract]   [Full Text] [Related]  

  • 10. Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals.
    Enomoto M; Tateishi C; Tsuruta D; Tamori A; Kawada N
    Ann Intern Med; 2018 May; 168(9):678-680. PubMed ID: 29335738
    [No Abstract]   [Full Text] [Related]  

  • 11. Shorter treatments for hepatitis C: another step forward?
    Foster GR
    Lancet; 2015 Mar; 385(9973):1054-5. PubMed ID: 25591504
    [No Abstract]   [Full Text] [Related]  

  • 12. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Younossi ZM; Jiang Y; Smith NJ; Stepanova M; Beckerman R
    Hepatology; 2015 May; 61(5):1471-8. PubMed ID: 25706754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus and Schizophrenia: Expanding the Role of the Community Psychiatrist.
    Herold S; Freudenreich O
    Psychosomatics; 2016; 57(6):634-637. PubMed ID: 27418108
    [No Abstract]   [Full Text] [Related]  

  • 14. Are we hopefully very close to the end of HCV?
    Tahan V
    Turk J Gastroenterol; 2014 Apr; 25(2):230-1. PubMed ID: 25003693
    [No Abstract]   [Full Text] [Related]  

  • 15. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
    Connolly MP; Kotsopoulos N; Ustianowski A
    J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HCV for porphyria cutanea tarda.
    Abdelmaksoud A
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133909
    [No Abstract]   [Full Text] [Related]  

  • 17. Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.
    Bruzzone B; Magnani O; Sticchi L; Canepa P; Rappazzo E; Icardi G; Setti M
    J Antimicrob Chemother; 2017 Oct; 72(10):2955-2958. PubMed ID: 29091216
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Drug Interactions in Patients Co-infected With HCV and HIV.
    Nozaki Y; Yanase M; Masaki N
    JAMA; 2015 Jul; 314(2):186. PubMed ID: 26172899
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.
    Osinusi A; Townsend K; Kottilil S
    JAMA; 2015 Jul; 314(2):186-7. PubMed ID: 26172900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.